TSRO TESARO, Inc.

139.01
-9  -6%
Previous Close 148.00
Open 144.50
Price To book 12.98
Market Cap 7.45B
Shares 53,626,000
Volume 3,954,308
Short Ratio 7.63
Av. Daily Volume 1,092,060

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 enrolling as of February 2017.
Niraparib and Keytruda (TOPACIO)
Triple-negative Breast Cancer or Ovarian Cancer
Phase 3 trial enrolling - February 2017.
Niraparib - PRIMA
First-line ovarian cancer
CRL issued January 11 2017.
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
Phase 3 trial no longer be expected to serve as a registration trial - noted March 27, 2017.
Niraparib - BRAVO
Cancer - breast
PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.
Niraparib - NOVA (Niraparib Ovarian)
Cancer - ovarian
Phase 2 data due 2H 2017.
Niraparib - (QUADRA trial)
Cancer - ovarian
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients